# Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)

> **NCT07509749** · PHASE2 · RECRUITING · sponsor: **Daihong Liu** · enrollment: 54 (estimated)

## Conditions studied

- GVHD, Acute
- Stem Cell Transplant Complications

## Interventions

- **DRUG:** Ruxolitinib and Methylprednisolone
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT07509749
- **Lead sponsor:** Daihong Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07509749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07509749, "Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07509749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*